New antileishmanial and antitrypanosomal drugs
Beschreibung
The aim is to develop a natural product derived LEAD compound with unrivalled potency against a parasitic disease into a clinical drug candidate, through preclinical development. This includes the establishment of a detailed structure-activity relationship (SAR), medicinal chemistry and organic synthesis, ADME-Tox optimization, formulation, and in vivo studies.
Eckdaten
Projektleitung
Projektteam
Dr. Michael Brand, Flavio Gall, Dr. Silvia Gazzola, Luka Raguz, Dr. Stefano Agnello
Projektpartner
BACOBA AG
Projektstatus
abgeschlossen, 09/2016 - 01/2019
Institut/Zentrum
Institut für Chemie und Biotechnologie (ICBT)
Drittmittelgeber
KTI-Projekt / Projekt Nr. 19208.1 PFLS-LS
Projektvolumen
2'043'672 CHF
Publikationen
-
Dissecting structural requirements of leucinostatin A derivatives for antiprotozoal activity and mammalian toxicity
2025 Rimle, Lukas; Pliatsika, Dimanthi; Arnold, Noëlle; Kurth, Sandra; Kaiser, Marcel; Mäser, Pascal; Kemmler, Michael; Adams, Michael; Riedl, Rainer; von Ballmoos, Christoph
-
Antiprotozoische Struktur‐Aktivitäts‐Beziehungen von synthetischen Leucinostatin‐Derivaten und Aufklärung ihres Wirkprinzips
2021 Brand, Michael; Wang, Lei; Agnello, Stefano; Gazzola, Silvia; Gall, Flavio; Raguž, Luka; Kaiser, Marcel; Schmidt, Remo S.; Ritschl, Amélie; Jelk, Jennifer; Hemphill, Andrew; Mäser, Pascal; Bütikofer, Peter; Adams, Michael; Riedl, Rainer
-
Antiprotozoal structure–activity relationships of synthetic leucinostatin derivatives and elucidation of their mode of action
2021 Brand, Michael; Wang, Lei; Agnello, Stefano; Gazzola, Silvia; Gall, Flavio; Raguž, Luka; Kaiser, Marcel; Schmidt, Remo S.; Ritschl, Amélie; Jelk, Jennifer; Hemphill, Andrew; Mäser, Pascal; Bütikofer, Peter; Adams, Michael; Riedl, Rainer
-
Antiprotozoal compounds
2018
Einsiedlerstrasse 31
8820 Wädenswil